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1. Introduction
The cause of the Duchenne muscular dystrophy (DMD) is deficiency of the dystrophin protein
leading to dysfunction of many organs. Originally it was thought that the natural history of
this disease limits the lifespan of the patients to 20 year. However, positive therapeutic
interventions for heart failure, respiratory failure, nutritional management, spinal surgery and
the rehabilitation raised the lifespan of patients with DMD in Japan above 30 years of age.
(Ishikawa Y, et al. 2011) (Matsumura T, et al. 2011) (Saito T, et al. 2011). Consequently,
nowadays complications accompanying the higher survival age of DMD patients should also
be considered. This chapter describes a coagulation and fibrinolysis abnormality of muscular
dystrophy, and its involvement in the microcirculation disorder accompanying this disease.
2. The old tale of DMD as a microcirculation disorder
Historically before the discovery of dystrophin, a hypothesis was proposed that blood
circulation insufficiency due to intravascular obstruction causes muscle necrosis in DMD. This
hypothesis was based on muscle histopathology findings similar to necrosis caused by
circulation insufficiency. There were some reports that tried to model the pathologic condition
of DMD with impaired circulation. However, these trials to reproduce the DMD pathology
were unsuccessful. (Bradley WG, et al. 1975) (Gudrun B, et al. 1975) (Leinonen H, et al. 1979)
Meanwhile Miike T, et al. described vascular obstruction and vascular endothelial hyperplasia,
namely the blister-like swelling of vascular endothelial cells in the muscle histopathology of
non-symptomatic children with DMD, and put forward a hypothesis of the blood flow
abnormality that affects the progress of DMD (Miike T, et al. 1987). After the discovery of
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dystrophin, the mainstream theory for the pathogenesis of DMD became the muscle destruc‐
tion due to the membranous fragility related to dystrophin defects. Since then the vascular
disorders in DMD have been regarded not important.
3. Thrombosis and embolization as complication of DMD
There are some reports related to thrombosis or embolization of patients with DMD.
In 1982, Matsuishi T, et al. reported a basilar artery occlusion in a case of DMD, in which the
pathogenesis of infarction was uncertain. (Matsuishi T, et al. 1982) In 1989, Gaffney JF, et al
reported left ventricular thrombus and systemic emboli complicating the cardiomyopathy of
DMD. (Gaffney JF, et al. 1989) Authors showed anteroseptal mural thrombus and right atrial
thrombus as autopsy findings. Riggs T also reported three terminal DMD cases of cardiomy‐
opathy and pulmonary emboli. (Riggs T. 1990) Author showed thrombus formation of
ventricle and pulmonary embolus with a ventilation perfusion scan.
The epidemiologic aspects of DMD-related thromboembolism were addressed by Biller J, et
al., who reported the frequency of cerebral infarction in patients with inherited neuromuscular
diseases including DMD, Becker muscular dystrophy (BMD), myotonic dystrophy, and
Freidrich ataxia. According to their data cerebral infarction was seen in 1. 5% of the cases with
these diseases and concluded that cerebral infarction is uncommon in neuromuscular diseases.
4. Pioneer studies of coagulation and fibrinolysis abnormalities of DMD
in Japan
Among annual reports of clinical research group for muscular dystrophy in Japan, some
reports described cases of cerebral infarction and pulmonary embolism in patients with DMD.
Ishihara T, et al. reported series of 15 autopsied cases of DMD/BMD with hemorrhagic
pulmonary infarction in 1990. He pointed out that this disorder is an important cause of death
in DMD. Matsuka Y, et al. reported a DMD case of cerebral infarction and thrombus formation
in the left ventricle in 1991, and described elevated levels of thrombin-antithrombin complex
(TAT) and platelet factor 4 (PF4) among many DMD cases with CTR>50% in 1993. Hanajima,
et al. reported the occurrence of cerebral infarction of DMD in muscular dystrophy wards in
Japan to be 5 / 269 DMD patients aged from 16 to 20 years old. Authors concluded that cerebral
infarction is not a rare complication of DMD. (Hanajima, et al. 1996)
Based on these findings the clinical research team for the genetic counseling and the clinical
research of the pathology and treatment in muscular dystrophy patients (from 1996 to 1998),
that was directed by Ishihara T, proposed a research and intervention project to investigate
the blood coagulation disorder complicating the muscular dystrophy. In next section, results
of the research in this team are described.
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5. Abnormal coagulation and fibrinolysis in DMD
Saito Y, et al. reported hypercoagulable state in patients with DMD. (Saito Y, et al. 1997) By
the blood coagulation test of patients with DMD and other neuromuscular diseases at rest
condition, the authors showed that abnormal findings appear in many coagulation and
fibrinolysis parameters such as thrombotest, TAT, and plasmin –α2 Plasmin inhibitor complex
(PIC) in DMD. Namely, level of thrombotest, which reflects coagulation activity including
effect of PIVKA (used for monitoring warfarin treatment), was low compared to normal range
in 78% of DMD, TAT level was elevated in 61% of DMD, and PIC level elevated in 40. 3% of
DMD. Abnormality of the coagulation and fibrinolysis was found in most patients with DMD.
The frequency of abnormality was high compared with other neuromuscular diseases.
In this report, the ratio of abnormal value of D-dimer and fibrin and fibrinogen degradation
products (FDP) was low in DMD, authors described that coagulation cascade is more enhanced
than fibrinolysis cascade in patients with DMD. The coagulation and fibrinolysis abnormality
was not associated with age, respiratory function, cardiac activity, and activities of daily living.
Authors concluded that muscular dystrophy itself is a risk factor for thrombosis.
Based on examination of relation with the muscle destruction Saito T, et al. reported that
coagulation and fibrinolysis abnormality is strongly present in younger patients with DMD,
BMD, and Fukuyama congenital muscular dystrophy (FCMD). (Saito T, et al. 2001) They showed
significant correlation between serum levels of FDP and MM isozyme of creatine kinase (CK-
MM), irrespective of type of dystrophy. Figure 1 shows correlation between FDP and CK-MM
of patients with DMD, whereas Figure 2 shows correlation between FDP and D-dimer. Levels
of FDP were higher at ambulatory young boy with high CK DMD. Authors speculated that
enhanced coagulation and fibrinolysis in DMD, BMD, and FCMD is induced by some compo‐
nents that leak from destructed muscle. It is inferred that the disturbances of the coagulation and
fibrinolysis result from the muscle destruction. Increase of both plasma levels of D-dimer and
serum levels of FDP is an indirect proof of thrombus having been present in vivo. It means that
microcirculation disorder is possibly present in DMD, BMD, and FCMD potentially.
In this study advanced DMD patients with low CK showed no abnormal elevation of FDP and
D-dimer. However, even DMD patients in advanced stage, whose CK levels were within
normal range, showed coagulation abnormalities, if serum CK increased as a consequence of
muscle destruction induced by various causative factors. Saito T, et al. reported activated
coagulation cascade in a case of advanced DMD that showed transient elevation of serum CK
due to convulsion. (Saito T, et al. 2003) These phenomena are possible sources of pulmonary
emboli accompanying DMD. Nakayama T, et al. established that CK elevation preceded the
development of pulmonary embolism in patients with DMD (Nakayama T, et al. 2000).
6. Abnormal coagulation and fibrinolysis in cases of dystrophinopathy
with heart failure
There is  evidence for association between cardiac dysfunction and coagulation disorder.
Saito T, et al. reported that levels of TAT and prothrombin fragment (F1+2) in DMD patients
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Figure 1. Correlation of serum FDP and CK-MM in patients with DMD, Serum CK-MM level is significantly correlated
with FDP. n=36, (modified figure of literature, Saito T, et al. 2001)
Figure 2. Correlation of serum FDP and plasma D-dimer in patients with DMD, Although correlation between FDP and
D-dimer was not significant, both FDP and D-dimer elevated in DMD patients. n=36 (modified figure of literature, Sai‐
to T, et al. 2001)
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with the markedly depressed cardiac function were significantly elevated compared to DMD
patients with preserved cardiac function. Authors concluded that activated coagulation is
associated with cardiac dysfunction in patients with DMD. (Saito T, et al. 2005) Porreca E,
et  al.  also  reported  similar  findings  in  patients  with  dystrophinopathy  including  BMD.
(Porreca E, et al. 1999) These abnormalities probably induce cerebral infarction through a
mechanism similar  to  the one observed in idiopathic  cardiomyopathy.  Ikeniwa C,  et  al.
reported two cases of DMD with dilated cardiomyopathy and cerebral infarction. (Ikeni‐
wa C, et al. 2006)
7. Studies of other factors affecting coagulation and fibrinolysis status
In addition to the cases described above, the clinical research group for muscular dystrophy
in Japan reported that infectious diseases activate coagulation cascade by increasing the level
of fibrinogen resulting in elevation of D-dimer. However, this acute-phase reaction induced
by infection is observed generally in normal subjects too.
An interventional study was also proposed in the form of a clinical trial to administer warfarin
for DMD/BMD patients with high risk of thrombosis. Within its framework information
regarding the coagulation status of 190 DMD/BMD patients in muscular dystrophy wards in
Japan was collected abnormal rate of TAT was 36. 0%, and that of F1+2 was 51. 2% in DMD
patients, which demonstrated that enhanced blood coagulation was dominant in DMD
patients. However, the number of patients recruited in this clinical trial was too small, so the
trial was not started. Instead of clinical trial, they proposed substitute treatment, namely
improving congestion in venous return of bedridden patients with DMD, and prevention of
dehydration.
8. Platelet abnormalities in DMD
Forst J, et al. reported a significant deficiency of platelet adhesion and ristocetin induced
aggregation as well as a marked reduction of expression of glycoprotein IV, although normal
plasmatic coagulation and a slight but not significant increase of bleeding time was observed
in DMD patients (Forst J, et al. 1998 ). Authors speculated that the platelet function deficiency
occurs because of a decompensation of platelet adhesion as well as aggregation capacity in
major spinal surgery, although the deficiency of platelet function in DMD patients does not
affect ordinary life or minor surgery.
Further, Matsumura T, et al. reported a case of DMD complicated by thrombotic thrombocy‐
topenic purpura (TTP). In their report, TTP was confirmed by decreased activity of von
Willebrand factor cleaving protease and activity plasma exchange was successful for the
patient (Matsumura T, et al. 2003).
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9. Pathogenetic aspects of the coagulation abnormalities in Duchenne
muscular dystrophy
From the point of view that coagulation disorders induce microcirculation abnormalities, Saito
T, et al. speculated that hypoxic and ischemic condition might exist in DMD. They reported
that elevated levels of VEGF are observed in dystrophinopathy patients, and supposed that
these are induced by relative hypoxic and ischemic condition. (Saito T, et al. 2009) However,
these conditions were marked in advanced DMD patients rather than young boy with DMD.
On the other hand, it has been considered that circulation abnormality may participate in
disease progression of DMD, which has not been evaluated for a long time since dominance
of membrane theory. (Lombard JH. 2011) Functional muscle ischemia has been reported in
patients with DMD. (Sander M, et al. 2000) Defect of nNOS due to dystrophin absence induce
functional muscle ischemia related muscle exercise, which can induce microcirculation
insufficiency of muscle tissue. Asai A, et al. reported effectiveness of Phosphodiesterase-5
Inhibitor to mouse model of muscular dystrophy by improving microcirculation of muscle
tissue. (Asai A, et al. 2007)
Figure 3. Muscle destruction process and the relation to coagulation and fibrinolysis adnormalities in DMD patients
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In Figure 3, I summarize the muscle destruction process and the relation to coagulation and
fibrinolysis adnormalities in DMD patients. The origin of DMD is dystrophin deficiency.
Dystrophin deficiency induces functional muscle ischemia as well as membrane fragility of
muscle, leading to muscle destruction. Muscle destruction activates coagulation and fibri‐
nolysis cascade (, which may be similar to rhabdomyolysis). Activated cascade induces mi‐
crocirculation insufficiency affecting functional muscle ischemia derive from dystrophin
deficiency. On the other hand, cardiomyopathy and arrhythmia cause thrombus formation
with mechanism similar to idiopathic dilated cardiomyopathy, which can cause cerebral in‐
farction and pulmonary embolism. Moreover, transient muscle damage even in advanced
DMD patients activates coagulation cascade leading to cerebral infarction and pulmonary
embolism.
Therefore, improving microcirculation insufficiency, and coagulation and fibrinolysis abnor‐
malities may lead to improving disease progression and prevention of complications in DMD
patients. Now, the level of peripheral circulating CD34 positive cells, namely endothelial
circulating progenitor cell related with vascular homeostasis, functional maintenance and
angiogenesis, is evaluated whether it can be the biomarker reflecting microcirculation
abnormality and disease progression of DMD (Saito T, et al. 2013).
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